News
ACRS
3.860
+2.93%
0.110
Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference
Reuters · 8h ago
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Barchart · 13h ago
Weekly Report: what happened at ACRS last week (0330-0403)?
Weekly Report · 2d ago
Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush
Dow Jones · 03/31 14:11
Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target
Benzinga · 03/31 14:01
Weekly Report: what happened at ACRS last week (0323-0327)?
Weekly Report · 03/30 09:07
Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selective Investigational Oral Covalent Inhibitor Of ITK And JAK3, At 2026 AAD Annual Meeting
Benzinga · 03/27 14:12
Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%
Reuters · 03/27 14:10
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
Barchart · 03/27 09:10
Weekly Report: what happened at ACRS last week (0316-0320)?
Weekly Report · 03/23 09:07
Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational Oral Covalent Inhibitor Of Interleukin-2-ITK And JAK3, At 2026 AAD Annual Meeting
Benzinga · 03/20 15:03
Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting
Reuters · 03/20 15:00
ACLARIS THERAPEUTICS ANNOUNCES POSTER ON RESULTS FROM PHASE 2A TRIAL OF ATI-2138 AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING
Reuters · 03/20 15:00
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Barchart · 03/20 10:00
Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 03/19 12:22
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
Benzinga · 03/19 12:12
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Aclaris Therapeutics (ACRS)
TipRanks · 03/19 10:41
Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis
Reuters · 03/18 10:55
ACLARIS THERAPEUTICS INC - TOP LINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2026
Reuters · 03/18 10:55
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV)
TipRanks · 03/16 10:30
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).